81 results
424B5
MRSN
Mersana Therapeutics Inc
28 Feb 24
Prospectus supplement for primary offering
4:07pm
, homogeneous ADCs. Dolasynthen allows for drug-to-antibody ratios to be optimized for specific targets and utilizes a proprietary auristatin payload
POS AM
MRSN
Mersana Therapeutics Inc
28 Feb 24
Prospectus update (post-effective amendment)
4:05pm
. Dolasynthen allows for drug-to-antibody ratios to be optimized for specific targets and utilizes a proprietary auristatin payload that has been shown
POSASR
MRSN
Mersana Therapeutics Inc
28 Feb 24
Automatic shelf registration (post-effective amendment)
8:43am
for specific targets and utilizes a proprietary auristatin payload that has been shown clinically to avoid dose-limiting severe neutropenia, peripheral
8-K
EX-99.1
pfjoa
28 Feb 24
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7:07am
8-K
EX-99.1
qbedqoh mc
5 Jan 24
Regulation FD Disclosure
8:06am
8-K
EX-99.1
sjc62bxw
7 Nov 23
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
7:18am
8-K
EX-99.1
rmoh1nao9xzgh
8 Aug 23
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8:04am
8-K
xg44wqhwxm u73f4
8 Aug 23
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
8:04am
S-3ASR
2qt1h6ameb06z2o4ir
9 May 23
Automatic shelf registration
4:10pm